MeiraGTx Holdings plc

NASDAQ:MGTX

Biotechnology

Healthcare
$8.32 +5.08%

+$0.53 today

Market cap
$813.12M
Beta
1.26
P/E (TTM)
-7.4
EPS (TTM)
-$1.48
52W Low $6.07High $11.85

Volume 0.58M

Average 0.84M

MGTX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

MeiraGTx Holdings plcNASDAQ: MGTX

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q1 FY2026 net income of $46.31M (cash outflow) rose 15.8% year over year, behind the +96.4% change in trailing-twelve-month net income. Sequentially, it fell 76.0% from the prior quarter. Over 3 fiscal years it compounded at -4.1% a year.

Context

  • Net income amounted to 140.3% of revenue in FY2025, down 303.8 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of $22.44M (+119.6%) for the fiscal year ending Dec 2026, a step up from the -22.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$46.31M-76.0% QoQ
Last fiscal yearDec 2025
-$114.2M-22.7% YoY
LTMMar 2026
-$328.6M+96.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.8%+14.5%-1.4 pp
1 year-22.7%+119.6%+142.4 pp
3-year CAGR-4.1%-11.9%-7.8 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(114.2M) USD
Year-over-year change
+22.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How MGTX compares with its peers on the latest reported figures

  • MGTX's LTM Mar 2026 net income of $328.6M is the 2nd largest of the 9 companies compared; the peer median is $184.88M.
  • Its year-over-year change of +96.4% is the 2nd highest of 9, against a peer median of +20.3%.
  • Net income amounts to 412.0% of revenue for MGTX, versus a peer median of 433.1%.
MGTX Competitors Peer median
Net Income for MGTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$500.92M -4.8%+3.1%757.9%
MGTXMeiraGTx Holdings plcLTM Mar 2026$328.6M +96.4%-4.1%412.0%
RGNXREGENXBIO Inc.LTM Mar 2026$290.01M +83.9%-11.6%330.2%
SANASana Biotechnology, Inc.LTM Mar 2026$241.99M +16.0%-3.2%—
KRYSKrystal Biotech, Inc.LTM Jun 2026$241.47M +64.6%—54.8%
QUREuniQure N.V.LTM Mar 2026$208.87M -4.0%+16.2%1154.4%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$160.9M -8.8%+9.2%182.3%
OCGNOcugen, Inc.LTM Mar 2026$71.67M +24.7%-7.9%1605.2%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$64.01M +294.9%+34.1%433.1%
Peer median (excluding MGTX) $184.88M+20.3%+3.1%433.1%

Competitors are the stored peer set for MGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(79.56M)(129.62M)(84.03M)(147.79M)(114.2M)
Depreciation & Amortization7.87M8.6M13.72M12.68M12.7M
Deferred Income Tax00000
Stock-Based Compensation20.78M28.62M27.72M25.19M22.11M
Change in Working Capital31.28M9.62M(983K)29.64M28.03M
Accounts Receivables16.7M5.17M4.83M9.43M(7.27M)
Inventory000(387K)428K
Accounts Payables13.35M3.74M2.33M10.74M(12.31M)
Other Working Capital1.23M713K(8.14M)9.87M47.18M
Other Non-Cash Items9.1M9.67M(61.8M)(24.22M)5.01M
Operating Cash Flow(10.53M)(73.1M)(105.37M)(104.5M)(46.36M)
Capital Expenditures(55.22M)(44.96M)(20.17M)(4.96M)(3.83M)
Acquisitions (Net)(6.5M)0000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0054.21M28.43M(281K)
Investing Cash Flow(61.72M)(44.96M)34.03M23.48M(4.11M)
Debt Repayment(1K)75M00(29K)
Common Stock Issued1.71M25M91.95M59.39M15.33M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(4.8M)(7.93M)(4.86M)(3.03M)
Financing Cash Flow1.71M95.2M84.02M54.53M12.27M
Effect of Forex Changes(1.28M)674K2.44M1.5M719K
Net Change in Cash(71.82M)(22.19M)15.13M(24.98M)(37.48M)
Free Cash Flow(65.75M)(118.06M)(125.54M)(109.45M)(50.19M)

MeiraGTx Holdings plc

NASDAQ:MGTX

Intrinsic Alpha fair value

Locked

Current Price

$8.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.